HSBC Holdings
FATE icon

HSBC Holdings’s Fate Therapeutics FATE Stock Holding History

HSBC Holdings’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$116K Hold
97,684
– – ﹤0.01% 2732
2025
Q4 		$96.2K Sell
97,684
-118
-0.1% -$142 ﹤0.01% 2796
2025
Q3 		$119K Sell
97,802
-5,164
-5% -$5.57K ﹤0.01% 2576
2025
Q2 		$118K Sell
102,966
-6,380
-6% -$7.42K ﹤0.01% 2818
2025
Q1 		$83.5K Sell
109,346
-76
-0.1% -$93 ﹤0.01% 2847
2024
Q4 		$179K Buy
109,422
+19,706
+22% +$49.7K ﹤0.01% 2749
2024
Q3 		$320K Buy
89,716
+1,202
+1% +$4.68K ﹤0.01% 2293
2024
Q2 		$283K Buy
88,514
+22,583
+34% +$98.9K ﹤0.01% 2321
2024
Q1 		$484K Sell
65,931
-12,816
-16% -$79.3K ﹤0.01% 2121
2023
Q4 		$295K Sell
78,747
-31,645
-29% -$74.7K ﹤0.01% 2292
2023
Q3 		$237K Buy
110,392
+75,039
+212% +$249K ﹤0.01% 2338
2023
Q2 		$169K Sell
35,353
-7,055
-17% -$38.9K ﹤0.01% 2360
2023
Q1 		$240K Sell
42,408
-1,390
-3% -$8.39K ﹤0.01% 2319
2022
Q4 		$438K Buy
43,798
+18,701
+75% +$351K ﹤0.01% 2344
2022
Q3 		$578K Buy
25,097
+14,623
+140% +$423K ﹤0.01% 2099
2022
Q2 		$258K Buy
10,474
+2,133
+26% +$58.9K ﹤0.01% 2724
2022
Q1 		$331K Buy
+8,341
New +$323K ﹤0.01% 2690
2021
Q3 		– Sell
-4,223
Closed -$368K – 3035
2021
Q2 		$368K Buy
+4,223
New +$340K ﹤0.01% 2386
2020
Q4 		– Sell
-12,391
Closed -$502K – 3068
2020
Q3 		$502K Sell
12,391
-3,461
-22% -$121K ﹤0.01% 1942
2020
Q2 		$544K Buy
15,852
+5,573
+54% +$166K ﹤0.01% 1785
2020
Q1 		$233K Buy
+10,279
New +$260K ﹤0.01% 2201

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HSBC Holdings's FATE Position: Q1 2026 in Review

HSBC Holdings held its Fate Therapeutics (FATE) position steady in Q1 2026 at 97,684 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #2732.

HSBC Holdings first reported a position in FATE in Q1 2020 and has held it in 21 quarters since. The position peaked at $578K in Q3 2022. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • HSBC Holdings held 97,684 shares of Fate Therapeutics worth $116K as of Q1 2026.
  • HSBC Holdings left its Fate Therapeutics share count unchanged in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2732 holding.
  • HSBC Holdings first reported a position in Fate Therapeutics in Q1 2020 and has held it in 21 quarters since.
  • HSBC Holdings's Fate Therapeutics position peaked at $578K in Q3 2022.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.